Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
Top Cited Papers
- 20 May 2011
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 47 (10), 1476-1483
- https://doi.org/10.1016/j.ejca.2011.04.030
Abstract
No abstract availableKeywords
Funding Information
- UK National Cancer Research Network
This publication has 23 references indexed in Scilit:
- Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study GroupJournal of Clinical Oncology, 2006
- Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?European Journal Of Cancer, 2004
- An Evidence-based Staging System for Cutaneous MelanomaCA: A Cancer Journal for Clinicians, 2004
- Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III StudyJournal of Clinical Oncology, 2004
- Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: Rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in ScandinaviaInternational Journal of Cancer, 2003
- Final Version of the American Joint Committee on Cancer Staging System for Cutaneous MelanomaJournal of Clinical Oncology, 2001
- Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic MelanomaJournal of Clinical Oncology, 1999
- Prognostic factors for survival of patients treated systemically for disseminated melanoma.Journal of Clinical Oncology, 1998
- Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trialsCancer Treatment Reviews, 1997
- Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)British Journal of Cancer, 1992